Bioverativ Inc buy stratec
Start price
22.01.18
/
50%
€93.98
Target price
22.01.18
€90.20
Performance (%)
-0.04%
End price
22.01.18
€93.94
Summary
This prediction ended on 22.01.18 with a price of €93.94. The BUY prediction by stratec for Bioverativ Inc closed nearly unchanged. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Bioverativ Inc | - | - | - | - |
| iShares Core DAX® | 0.463% | -1.999% | 9.981% | 58.545% |
| iShares Nasdaq 100 | -1.792% | -5.743% | -0.781% | 80.511% |
| iShares Nikkei 225® | 5.124% | 9.091% | 28.823% | 62.776% |
| iShares S&P 500 | -1.760% | -3.669% | -0.543% | 54.389% |
Comments by stratec for this prediction
In the thread Bioverativ Inc diskutieren
stratec stimmt der Buy-Einschätzung von zeckenjoe zu
- Sanofi (NYSE:SNY) is close to acquiring Bioverativ (NASDAQ:BIVV) for $105 a share, valuing the hemophilia drug maker - separated from Biogen (NASDAQ:BIIB) last year - at about $11.6B, according to multiple reports.
- Sanofi
expects the purchase to be immediately accretive to its EPS in the 2018
full financial year, up to 5% accretive for the following year and
achieve a ROIC in excess of the cost of capital before 2021. - Update: In a press release, Sanofi confirmed that it will acquire Bioverativ for $11.6B. BIVV is up 62% premarket on modest volume. SNY is down 3% on average volume.
(Vom Mitglied beendet)